Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

OPDP Director Tom Abrams cautions against reading into the “snapshot.”

You may also be interested in...



Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study

US agency disagrees that study of consumer and healthcare professional ability to detect deceptive promos is unnecessary; final guidance on product name placement in labeling and advertisements mirrors 2013 draft.

FDA Lull In Rx Promotion Citations Continues; Guidances May Be Bigger Priority

Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.

FDA Closes 2013 With Flurry Of Citations For Misleading Rx Promotions

Office of Prescription Drug Promotion issues 23 letters in 2013, five less than the previous year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel